Galderma
As of the edition of 20 October 2026, Galderma runs 13 drugs, 13 of them marketed; it is on route A at 0 targets and on route B at 4 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 13 |
| Total | 13 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Metronidazole | none listed | 0 |
| Doxycycline anhydrous | none listed | 4 |
| Ivermectin | none listed | 0 |
| Brimonidine | none listed | 9 |
| Calcitriol | none listed | 2 |
| Adapalene | none listed | 9 |
| Fluocinolone acetonide | none listed | 1 |
| Clobetasol propionate | none listed | 2 |
| Nemolizumab | Ends 2036 (computed from the first US licence) | 2 |
| Methyl aminolevulinate | none listed | 0 |
| Trifarotene | Ends 2031 (patent) | 2 |
| Hydrocortisone butyrate | none listed | 1 |
| Desonide | none listed | 3 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 4 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Galderma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.